Neutropenia predicts better prognosis in patients with metastatic gastric cancer on a combined epirubicin, oxaliplatin and 5-fluorouracil regimen
Metrics: PDF 924 views | HTML 1068 views | ?
Rujiao Liu1,2,*, Mingzhu Huang1,2,*, Xiaoying Zhao1,2, Wei Peng1,2, Si Sun1,2, Jun Cao1,2, Dongmei Ji1,2, Chenchen Wang1,2, Weijian Guo1,2, Jin Li1,2, Jiliang Yin1,2, Xiaodong Zhu1,2
1Department of Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai, P.R. China
2Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, P.R. China
*These authors have contributed equally to this work
Xiaodong Zhu, e-mail: email@example.com
Keywords: metastatic gastric cancer, EOF5 regimen, chemotherapy-induced neutropenia, overall survival, progression-free survival
Received: April 21, 2015 Accepted: October 06, 2015 Published: October 16, 2015
Chemotherapy-induced neutropenia (CIN) reportedly indicated better prognosis for some cancers. We retrospectively analyzed 150 evaluable metastatic gastric cancer (MGC) patients who had received first-line EOF5 (combination regimen of epirubicin, oxaliplatin and 5-day continuous infusion of 5-fluorouracil) treatment. We divided patients into three groups according to the worst grade of CIN: absent group (grade 0), moderate group (grade 1–2) and severe group (grade 3–4). Multivariate analyses of overall survival (OS) proved moderate and severe CIN were important prognostic factors whether regarding CIN as a time-varying covariate (TVC) or not. Compared with absent CIN, hazard ratio (HR) for moderate and severe CIN were 0.31 (95% confidential interval (CI): 0.17–0.55; P < 0.001) and 0.36 (95% CI: 0.20–0.64; P = 0.001) respectively with TVC; and were 0.31 (95% CI: 0.17–0.56; P < 0.001) and 0.34 (95% CI: 0.19–0.61; P < 0.001) respectively without TVC. In progression-free survival (PFS) analyses, moderate and severe CIN showed similar results. In the landmark group (n = 122 patients) analyses with TVC, moderate and severe CIN remained prognostic factors for PFS, while only moderate CIN was prognostic factor for OS. CIN predicted longer OS and PFS in MGC patients treated with first-line EOF5 chemotherapy.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.